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Abstract: Atrial fibrillation (AF) is the most common form of cardiac arrhythmia and is 
associated with an increased risk of cardiovascular morbidity and mortality, especially due to 
ischemic stroke. The occurrence of AF leads to atrial electrical and structural remodeling. The 
renin-angiotensin system appears to play a role in the development of atrial arrhythmias by its 
involvement in both of these processes. Large-scale hypertension trials and heart failure trials 
have indicated the potential value of angiotensin II receptor blockers in the treatment of AF.
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Introduction
Atrial fibrillation (AF) is the most common clinically significant cardiac arrhythmia. 
Overall, it affects 1% of the population and is common in the elderly, with a 
prevalence of almost 10% in individuals aged over 75 years.1 Currently, approximately 
2.3 million people in the United States are diagnosed with AF, and this number is 
expected to rise to 5.6 million by 2050.2–4
A 38-year follow-up review of data from the Framingham Study has indicated that 
men have a 1.5-fold greater risk of developing AF than women and that hypertension 
and diabetes are significant independent predictors of AF, after adjustment for age 
and other predisposing conditions. Hypertension was shown to be the most common, 
independent, and potentially modifiable risk factor for AF,5,6 primarily because of its 
high prevalence in the population.5 The cardiac conditions that pose the greatest risk 
for development of AF include heart failure, myocardial infarction, and valvular heart 
disease (especially mitral valve disease). In addition, other cardiac conditions that 
have been associated with the occurrence of AF include myocarditis, hypertrophic 
cardiomyopathy, congenital heart disease, pericarditis, hypertensive cardiovascular 
disease, left ventricular hypertrophy, and coronary artery disease.5,7 Obesity was not 
associated with the incidence of AF in the review of Framingham data.5 However, it 
has been proposed as a risk factor for the development of AF in relation to associated 
left atrial dilation.8
The development of AF has been associated with a 1.5- to 1.9-fold greater mortality 
risk, after adjusting for preexisting cardiovascular conditions, in the original cohort of 
the Framingham Study.9 Much of the morbidity and mortality associated with AF is 
due to thromboembolic complications resulting in ischemic stroke, especially in the 
elderly.10 Ischemic stroke incidence among patients with nonvalvular AF averages 5% 
per year and is approximately 2 to 7 times greater than in individuals without AF.11Vascular Health and Risk Management 2009:5 784
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The occurrence of AF leads to atrial electrical and 
structural remodeling, which both contribute to the main-
tenance and recurrence of the arrhythmia.12–18 Patients who 
initially present with paroxysmal AF often progress to longer, 
non–self-terminating bouts,19 and enlarged atria are a major 
risk factor for its recurrence.20,21
Current treatment strategies for AF include the prevention 
of thromboembolism and either rate-control or rhythm-
control strategies, with pharmacotherapy or left atrial ablation 
as first- or second-line therapy options, respectively.8 These 
approaches may produce similar outcomes, but rate control 
may be preferable because agents used to maintain sinus 
rhythm can have proarrhythmic effects. However, both 
approaches have important limitations, including proar-
rhythmic and negative dromotropic effects, respectively.8,22,23 
In view of this, a preventive strategy may be a more attrac-
tive option.7 The angiotensin-converting enzyme (ACE) 
inhibitors have been shown to reduce the incidence of AF 
postmyocardial infarction and in patients with left ventricu-
lar dysfunction.24,25 In addition, in recent years, large-scale 
hypertension trials (Losartan Intervention For Endpoint 
reduction in hypertension [LIFE] and Valsartan Antihy-
pertensive Long-term Use Evaluation [VALUE]) and heart 
failure trials (Candesartan in Heart Failure – Assessment 
of Mortality and Morbidity [CHARM] and Valsartan Heart 
Failure Trial [Val-HeFT]) have indicated the potential value 
of angiotensin II receptor blockers (ARBs) in the treat-
ment of AF.26–30 The aim of this review is to examine the 
mechanisms of action and clinical efficacy of ARBs in the 
prevention of AF.
Preventive mechanisms  
of ARBs in AF
The occurrence of uncomplicated AF leads mainly to 
electrical remodeling due to the high atrial rate (indicated by 
shortening of refractoriness), whereas structural remodeling 
develops when AF leads to a hemodynamic burden on the 
atria.31 Cellular electrophysiological studies have indicated 
that marked reductions occur in the densities of the L-type 
voltage-gated calcium (Ca2+) current, I(Ca, L), the transient 
outward potassium (K+) current, I(TO), and the ultra-rapid 
delayed rectifier K+ current, I(Kur) in atrial myocytes from 
patients with chronic AF. Similar changes in currents have 
been noted in myocytes from a canine model of AF.32 In both 
human and canine AF, the reduction in I (Ca, L) may explain 
the observed decrease in action potential duration and 
effective refractory period that are characteristic electro-
physiological features of the remodeled atria.32 Thus, it has 
been suggested that calcium overload and perturbations in 
calcium handling play prominent roles in AF-induced atrial 
remodeling in humans.32
In addition, angiotensin II exerts its physiologic effects 
by activating AT1 and AT2 receptor subtypes. Goette et al 
noted that the occurrence of AF was associated with down 
regulation of AT1 and upregulation of AT2.33 However, 
recently von Lewinski et al reported data that suggests that 
the major arrhythmic effects occur secondary to stimulation 
of the AT1 receptor and thus blockade of the AT1 receptor 
may be antiarrhythmic.34
In contrast, structural remodeling is associated with 
fibrosis: this is characterized by increased deposition of 
connective tissue in the atria. The histological substrate of 
atrial biopsies in patients with lone AF has suggested that the 
probability of AF increases as the degree of fibrosis increases, 
and further electrophysiologic modification ultimately leads 
to self-perpetuation of AF.31,35–39
The renin-angiotensin-aldosterone system (RAAS) 
appears to play a role in the development of arrhythmias by 
its involvement in both forms of remodeling. For example, 
angiotensin II has been shown to play a critical role in 
cardiac remodeling via the promotion of cardiac myocyte 
hypertrophy and cardiac fibroblast interstitial fibrotic changes 
associated with left ventricular hypertrophy, postmyocardial 
infarction remodeling, and congestive heart failure (CHF).40 
In particular, angiotensin II has been shown to mediate car-
diac myocyte hypertrophy directly via induction of immedi-
ate early genes through a mitogen-activated protein kinase 
(MAPK)-dependent pathway. In addition, it has also been 
shown to mediate cardiac hypertrophy indirectly via stimula-
tion of norepinephrine release from cardiac nerve endings 
and endothelin from endothelial cells and through multiple 
effects on cardiac fibroblasts.40–45
Electrical remodeling is brought about by the shortening 
of the atrial effective refractory period (AERP) and of the 
action potential duration.46–49 The inhibitory effects of an 
ARB (candesartan) and an ACE inhibitor (captopril) on atrial 
electrical remodeling induced by rapid pacing have been 
examined in a canine model of AF.50 The AERP was mea-
sured before, during, and after rapid atrial pacing; infusions of 
saline, ARB, ACE inhibitor, or angiotensin II were initiated 
30 minutes before rapid pacing and continued throughout the 
study. In the saline and angiotensin II groups, the AERP was 
significantly shortened during rapid atrial pacing and the rate 
adaptation of the AERP was lost. In contrast, in the ARB and 
ACE inhibitor groups, shortening of the AERP after rapid 
pacing was completely inhibited and the rate adaptation of Vascular Health and Risk Management 2009:5 785
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the AERP was preserved, which indicated that endogenous 
angiotensin II may be involved in the mechanism of atrial 
electrical remodeling.50
In addition to the reduction of blood pressure per se, 
there are a range of other potential mechanisms by which 
inhibition of the RAAS may reduce AF (Figure 1).51 For 
example, blockade of the RAAS may prevent left atrial 
dilatation, atrial fibrosis, dysfunction, and slowing of 
conduction velocity44,50,52,53 and, thus, may be particularly 
effective in patients with left ventricular dysfunction/heart 
failure.54 Inhibition of the RAAS has also been shown to 
reduce inflammation and oxidative stress, and to modulate 
sympathetic nerve activity.55 The use of agents that block the 
RAAS has been shown to increase the efficacy of electrical 
cardioversion of AF,56–59 and some studies have also indicated 
that blockade of the RAAS by ARBs may have direct antiar-
rhythmic properties.60,61 Thus, inhibition of the RAAS may 
lead to improvements in the management of AF.
Clinical trials with ARBs in AF
A range of clinical and experimental studies have shown 
that the use of ACE inhibitors or ARBs in CHF reduces the 
occurrence of AF and AF vulnerability via the reduction of 
atrial structural remodeling and fibrosis.44,53,54,62–66
ARBs in patients with heart failure
A secondary analysis of the results of the CHARM program, 
which included 7601 patients with symptomatic CHF, has 
demonstrated that, in addition to significant reductions in 
cardiovascular deaths and hospital admissions for heart 
failure with reduced ejection fraction, the ARB candesartan 
significantly reduced the development of new AF compared 
with placebo. Moreover, the benefits of treatment with 
an ARB were accrued regardless of treatment at baseline 
(which included treatment with ACE inhibitors) and in 
a wide spectrum of patients with CHF, including those 
with preserved as well as reduced left ventricular systolic 
RAS ARBs
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Figure 1 Possible preventive mechanisms of ARBs in atrial fibrillation. Reproduced with permission from Aksnes T, Flaa A, Strand A, et al. Prevention of new-onset atrial 
fibrillation and its predictors with angiotensin II receptor blockers in the treatment of hypertension and heart failure. J Hypertens. 2007;25:15–23.51 Copyright © wolters 
Kluwer Health.
Abbreviations: ARBs, angiotensin II receptor blockers; RAS, renin-angiotensin-aldosterone system.Vascular Health and Risk Management 2009:5 786
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function (Table 1).67,68 In Val-HeFT, the occurrence of AF 
was associated with worse outcomes and was evaluated 
on the basis of adverse event reports in patients with heart 
failure treated with valsartan vs placebo on top of optimal 
heart failure therapy, which included ACE inhibitors and 
beta-blockers.69,70 Treatment with valsartan significantly 
reduced the combined endpoint of mortality and morbidity 
and improved clinical signs and symptoms in patients with 
heart failure, and also significantly reduced new-onset AF and 
reduced the relative risk of developing AF by 37% compared 
with placebo, when added to prescribed therapy. However, 
when ECG recordings from patients with sinus rhythm at 
enrolment were evaluated at 4, 12, and 24 months and at 
study end, the presence of at least 1 episode of AF showed no 
statistically significant difference between valsartan-treated 
patients and the placebo group (3.9% and 4.5%, respectively; 
P = 0.15) (Table 1).69,70
ARBs in the treatment of AF  
after cardioversion
The efficacy of treatment with irbesartan in maintaining 
sinus rhythm after cardioversion has been evaluated in 
patients with persistent AF.56 Patients were divided into 
2 groups: group 1 was treated with amiodarone, group 2 
with amiodarone plus irbesartan, and both groups under-
went electrical cardioversion after 3 weeks of amiodarone 
administration. All patients started amiodarone after at 
least 3 weeks of anticoagulation to achieve an international 
normalized ratio greater than 2, and the primary endpoint 
of the study was the length of time to the first recurrence 
of AF. After 2 months of follow-up, the amiodarone plus 
irbesartan group had significantly fewer recurrences of 
AF (63.2%) than the amiodarone-only group (84.8%, 
P = 0.008), and had a greater probability of maintaining 
sinus rhythm (79.5% vs 55.9%, P = 0.007).56 There was 
also a trend toward a lower number of shocks and lower 
electrical threshold, but this did not reach statistical 
significance.56 Furthermore, in a subsequent study, the 
combination of irbesartan plus amiodarone decreased 
the rate of AF recurrence in a dose-dependent manner in 
lone AF patients.57
ARBs in the prevention of new AF
In the Study on Cognition and Prognosis in the Elderly 
(SCOPE), there was a marked reduction in nonfatal stroke 
compared with placebo in elderly patients with hypertension 
who received treatment with an ARB, which may have been 
due to a reduction in AF (Table 2).71
Similarly, the results of the LIFE study indicated that 
ARB-based treatment produced a 25% reduction in fatal 
and nonfatal stroke compared with atenolol-based treatment 
in hypertensive patients with left ventricular hypertrophy. 
This was attributable in part to a 45% lower rate of stroke 
(24.1 vs 46.5 strokes per 1000 patient-years of follow-up) 
on ARB treatment in patients with a history of AF,29 but 
may have also been a reflection of benefits from a reduced 
incidence of new-onset AF. In a subsequent subanalysis of 
ECG data from patients without AF by history at baseline, 
new-onset AF occurred in 150 patients randomized to 
losartan vs 221 to atenolol (6.8 vs 10.1 per 1000 person-years; 
relative risk [RR] 0.67, P  0.001) despite similar levels of 
blood pressure reduction (Table 2).28 Patients who received 
losartan tended to stay in sinus rhythm longer (mean, 
1809 vs 1709 days from baseline, P = 0.057) than those 
who received atenolol. Patients with new-onset AF had 2-, 
3-, and 5-fold increased rates, respectively, of cardiovascular 
events, stroke, and hospitalization for heart failure, but there 
were fewer composite endpoints and strokes in patients who 
developed new-onset AF in the losartan arm compared to the 
atenolol treatment arm of the study.28
Table 1 The effects of ARBs on AF and outcomes in clinical trials in patients with left ventricular dysfunction/congestive heart failure
Study Design/follow-up N Interventions AF-related endpoints
CHARM67,68 MC, R, DB, PL 7601 Candesartan (Can) incidence of AF
Mean, 37.7 months PL 392/6379 (6.15%) of patients with no AF at baseline 
developed AF during follow-up
Can 5.55% vs PL 6.74% (OR 0.802, P = 0.039)
Val-HeFT substudy69,70 MC, R, DB, PL 4395 Valsartan (Val) incidence of AF
Mean, 23 months PL 287/4395 (6.35%) of patients with sinus rhythm at 
baseline had AF as an adverse event during follow-up
Val 5.12% vs PL 7.95% (P = 0.0002)
Note: Trial acronyms are expanded in the text.
Abbreviations: AF, atrial fibrillation;   ARB, angiotensin II receptor blocker; DB, double-blind; MC, multicenter; OR, odds ratio; PL, placebo-controlled; R, randomized.Vascular Health and Risk Management 2009:5 787
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In the VALUE trial, new-onset AF was a secondary 
prespecified endpoint and ECG recordings were obtained 
every year and centrally analyzed. During the study, the 
incidence of at least 1 documented occurrence of new-onset 
AF was significantly lower in the valsartan treatment group 
(3.7%) than in the amlodipine treatment group (4.3%, odds 
ratio 0.84) (Table 2). The incidence of persistent AF was 
also significantly lower with valsartan than with amlodipine 
(odds ratio 0.68, Table 2), and the effects of valsartan 
on the incidence of AF remained significant even when 
potential confounding covariates (age, history of coronary 
artery disease, left ventricular hypertrophy) were taken into 
account.27,30
In addition, the noninferiority of ARBs compared to 
ACE inhibitors in the prevention of new-onset AF was dem-
onstrated in the ONTARGET study (Ongoing Telmisartan 
Table 2 Studies of the effectiveness of ARBs in the prevention of AF (new onset and recurrent)
Study Design/follow-up N Interventions AF-related endpoints
New-onset AF
  SCOPe71 MC, R, DB, hypertension 
(elderly)
4964 Candesartan (Can) 
PL
incidence of nonfatal stroke  
Can 7.4 vs PL 10.3/1000 patient-years  
(risk reduction 27.8%, P = 0.04)
Mean, 3.7 years
  LiFe28 MC, R, DB, 
hypertension/LVH
8851a Losartan (Los) incidence of AF
Mean, 4.8 years Atenolol (At) Los 6.8 vs At 10.1/1000 patient-years  
(RR 0.67, P  0.001)
Maintenance of sinus rhythm
Los 1809 ± 225 days vs At 1709 ± 254 days 
(P = 0.057)
 VALUe27,30 Retrospective analysis 
of MC, R, DB study 
(hypertension)
15,245 Valsartan (Val) 
Amlodipine (Aml)
incidence of new-onset AF  
Val 3.7% vs Aml 4.3% (P = 0.044)  
Rate of persistent AF
Mean, 4.2 years Val 1.4% vs Aml 2.0% (P = 0.005)
  ONTARGeT72 MC, R, DB, patients at 
high risk of vascular 
events
25,620 Telmisartan (Tel) 
Ramipril (Ram)
incidence of new-onset AF  
Tel 6.7% vs Ram 6.9% vs Ram ± Tel 6.5%  
(all P = NS between treatments; Tel vs Ram 
RR 0.97) Median, 56 months Ram ± Tel 
combination therapy
Recurrent AF
  Fogari et al73 R, open-label,  
hypertension/type 2  
diabetes/AF
296 Valsartan (Val) 
Atenolol (At)
incidence of recurrent AF 
Val ± Aml 20.3% vs At + Aml 34.1% (P  0.01)
1 year (± Amlodipine [Aml])
  Fogari et al74 R, DB, hypertension/AF 
1 year
369 Valsartan (Val) 
Ramipril (Ram) 
Amlodipine (Aml)
incidence of recurrent AF  
Val 16.1% vs Ram 27.9% vs Aml 47.4% 
(P  0.01 Val vs Aml and P  0.05 Val vs Ram)
  GiSSi-AF75 MC, R, DB, PL, AF 1442 Valsartan (V) incidence of recurrent AF
Median, 1 year PL Val 51.4% vs PL 52.1% (HR 0.99), but trend 
favored Val in patients with CHF and/or LV 
dysfunction (HR 0.81)
  CAPRAF76,77 R, DB, PL, AF 171 Candesartan (Can) incidence of recurrent AF
6 months PL Can 71% vs PL 65% (P = 0.20) in patients 
with persistent AF who underwent eCV
Note:   aNo AF at baseline.
Abbreviations: AF, atrial fibrillation; ARB, angiotensin II receptor blocker; CHF, congestive heart failure; DB, double-blind; ECV, electrical cardioversion; HR, hazard ratio; 
LVH, left ventricular hypertrophy; MC, multicenter; PL, placebo; R, randomized; RR, relative risk.   Trial acronyms are expanded in the text.Vascular Health and Risk Management 2009:5 788
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Alone and in Combination With Ramipril Global Endpoint 
Trial) in patients with vascular disease or high-risk diabetes 
(Table 2).72 In this study, which compared the effectiveness 
of telmisartan and ramipril in reducing cardiovascular death, 
myocardial infarction, stroke, and hospitalization for heart 
failure in patients at risk, the diagnosis of new-onset AF was 
a secondary endpoint.72 Telmisartan treatment produced a 
greater reduction in blood pressure than ramipril and, after 
a median follow-up of 56 months, the primary outcome of 
death from cardiovascular causes, myocardial infarction, 
stroke, or hospitalization for heart failure had occurred in 
1412 patients in the ramipril group (16.5%) vs 1423 patients 
in the telmisartan group (16.7%, RR 1.01). However, the 
combination of the 2 drugs was associated with a greater fre-
quency of adverse events without an increase in benefit.72
ARBs in the prevention of recurrent AF
Patients with hypertension and type 2 diabetes have an 
elevated risk of cardiovascular events and typically require 
combination antihypertensive therapy to achieve goal blood 
pressure levels. In view of this, Fogari et al73 compared 
the effectiveness of valsartan + amlodipine and atenolol + 
amlodipine combinations on the prevention of AF recurrence 
in hypertensive patients with well-controlled type 2 diabetes 
in sinus rhythm who had at least 2 ECG-documented epi-
sodes of AF in the previous 6 months. Significantly fewer 
patients who were followed up for 1 year had recurrent AF 
with an ARB in addition to antiarrhythmic agents than with 
atenolol (Table 2).73 Overall, despite similar levels of blood 
pressure reduction, the valsartan + amlodipine combination 
was more effective in preventing AF in patients treated with 
amiodarone or propafenone.73 In addition, ARB therapy with 
valsartan led to significantly fewer recurrences of AF after 
12 weeks of treatment than amlodipine, and significantly 
less recurrence than both amlodipine and ramipril after 
1 year in patients with mild hypertension and a history of 
AF (Table 2).74 Although blood pressure lowering could be 
a beneficial mechanism of action for the reduction of AF 
with both types of RAAS inhibitors, there were no statisti-
cally significant differences in blood pressure between the 
3 treatment groups in this study. This suggested that both 
ARBs and ACE inhibitors may exert an antiarrhythmic 
effect beyond their effects on blood pressure.74 However, no 
statistically significant reduction in the recurrence of AF was 
noted with valsartan treatment compared with placebo in the 
recent GISSI-AF study (Gruppo Italiano per lo Studio della 
Sopravvivenza nell’Infarto Miocardico: Use of Valsartan and 
Angiotensin II AT1-Receptor Blocker in the Prevention of 
Atrial Fibrillation Recurrence).75 This may have been due to 
issues relating to the study design, broad selection criteria, 
and/or the patients’ relatively low-risk clinical conditions 
(and possible consequent low level of RAAS activation), 
and optimized background therapy. Moreover, the use of 
candesartan had no influence on echocardiographic variables 
or on the recurrence rate of AF after cardioversion in the 
6-month Candesartan in the Prevention of Relapsing Atrial 
Fibrillation (CAPRAF) study.76,77
Ongoing trials of ARBs in AF
It is hoped that a range of ongoing and planned future studies 
will help to clarify the possible beneficial effects of treatment 
with ARBs in terms of prevention of AF complications and 
prevention of AF recurrence (Table 3). The Atrial Fibrillation 
Clopidogrel Trial with Irbesartan for Prevention of Vascu-
lar Events (ACTIVE I) trial will randomize 9000 patients 
with a history of AF to receive irbesartan or placebo with 
a planned mean follow-up of 3 years. ACTIVE I is part of 
the ACTIVE trial program investigating the effect of irbe-
sartan on the occurrence of stroke, myocardial infarction 
or vascular death, hospitalization for heart failure (primary 
endpoints) and recurrence of AF, development of cardiac 
structural remodeling, microalbuminuria, cognitive function, 
and quality of life (secondary endpoints).78 In addition, the 
Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation 
(ANTIPAF) trial will compare the effect of olmesartan and 
placebo in patients with paroxysmal AF,79 and the aim of the 
planned I-PACE trial is to investigate the effects of irbesartan 
in hypertensive patients with pacemakers who have recur-
rent atrial high-rate episodes (Irbesartan for the Prevention 
of Atrial Arrhythmias and Cardiac Electrical Remodeling in 
Patients With Hypertension and Permanent Pacemakers).80
Conclusions and clinical 
recommendations
The prevention of AF is particularly challenging because 
of its high incidence.1,3,81 Because ARBs block the actions 
of angiotensin II, it seems likely that they interfere with 
structural and electrical remodeling and consequently pro-
vide benefits in terms of prevention of new-onset AF and 
recurrence of AF. So far, the body of evidence supports 
that ARBs may be useful in combination with other antiar-
rhythmic agents and not as sole antiarrhythmic therapy in 
suppressing AF recurrences. However, while the possibility 
of hemodynamic benefits and direct antiarrhythmic effects 
cannot be excluded, it is hoped that the results of ongoing pro-
spective studies, such as ACTIVE I and I-PACE, will clarify Vascular Health and Risk Management 2009:5 789
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the benefits of ARB treatment in relation to AF. Although 
valsartan was ineffective in suppressing AF in GISSI-AF, this 
study and the results of ACTIVE I may be limited by the high 
percentage of patients who had background ACE inhibitor 
therapy. The results of ACTIVE I may support the use of 
ARBs related to meaningful endpoints and not surrogates 
such as AF recurrence. Although it is not currently possible 
to specifically recommend the use of ARBs for prevention of 
AF in routine clinical practice, ARBs are well tolerated and 
may be considered for use in patients with AF and coexist-
ing clinical conditions such as hypertension, coronary heart 
disease, CHF, and type 2 diabetes.
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